Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| EDIPE | N/A |
Not yet recruiting |
Pre-Eclampsia|Hypertension|Pregnancy Outcomes |
2026-05-01 |
2023-08-22 |
Primary Endpoints|Treatments |
|
| ChiCTR1900027080 | N/A |
Recruiting |
Coronary Disease|Ventricular Dysfunction, Left|Hypertension|Diabetes Complications|GNE Myopathy|Heart Failure, Diastolic|Dyspnea|Heart Failure, Systolic|Heart Failure, Chronic |
2022-12-31 |